Wall Street tells AbbVie's story as a pipeline story: Skyrizi and Rinvoq growing fast enough to outrun Humira's decline. That framing misses the actual throttle. Under the Biologics Price Competition and Innovation Act (BPCIA), a biosimilar doesn't just need FDA approval to compete — it needs an interchangeability designation to be swapped for Humira at the pharmacy counter without a new prescription. And whether that swap actually happens depends on a second, less-watched layer: state pharmacy practice laws that decide if and how pharmacists execute the substitution. That combination — federal designation plus state execution — is a policy clock, not a science clock, and it has already re-rated one of the largest revenue bases in pharma. AbbVie's U.S. Humira sales have fallen roughly 38% since biosimilars entered in 2023, and the FDA's Purple Book now lists ten approved adalimumab biosimilars, most carrying interchangeable status. Every new interchangeability ruling and every state that tightens or loosens substitution rules moves billions in prescription volume — a lever AbbVie itself doesn't hold.